Found 15 clinical trials
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- 0 views
- 15 Mar, 2022
- 1 location
Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies
This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective
- 0 views
- 10 Mar, 2022
- 1 location
Study in Subjects With Relapsed/Refractory Follicular Lymphoma
designed to evaluate the efficacy and safety of tazemetostat in combination with lenalidomide and rituximab (R2) in subjects with relapsed or refractory (R/R) follicular lymphoma (FL), who have completed
- 2 views
- 15 Jul, 2022
- 105 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …
- 1032 views
- 25 Jul, 2022
- 106 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination
- 0 views
- 25 Jul, 2022
- 2 locations
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.
- 0 views
- 21 Mar, 2022
- 9 locations
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been
- 0 views
- 21 Mar, 2022
- 1 location
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has
- 44 views
- 27 Jul, 2022
- 23 locations
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)
Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to
- 10 views
- 27 Jan, 2022
- 31 locations
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment
- 0 views
- 18 Apr, 2022
- 17 locations
- 1
- 2